A92: Endo chemotherapy in cancer bladder no muscle invasive

Messaoud AYAD1,2,Neoual AKSIL1

1Centre anti cancer, Blida, Algeria,2University 1 medical college, Blida, Algeria

Presenting date: Monday 2 November
Presenting time: 13.10-14.00


At initial diagnosis, 75-85% of tumors are tumors of the bladder no muscle invasive: 60 to 70 % of lesions reoffend in the first year and 10-20% will progress to invasive tumors and / or metastatic. Prevention of bladder tumors are not infiltrating the muscle based on the fight against the main risk factors are smoking and occupational exposure (chemical carcinogens)


This is a single center study conducted in our service centric involving patients recruited to the consultation with bladder cancer without muscle invasive and requires chemotherapy instillations into the bladder. The objective of this study is to evaluate disease-free survival of these patients after chemotherapyure (chemical carcinogens)



A total of 130 patients were treated between 2009 and 2012, the median age was 64 years (45-83 years), the most common histological type was 47.5 % in urethelial carcinoma cases, the protocol used was an instillation of mitomycin C at a dose of 40 mg every week for 8 weeks, the observed toxicity was a bladder infection in 25 cases after 1144 cycles. The median disease-free survival was 15 months, and 04 recurrences that infiltrated the bladder muscle.


In our study, bladder endo chemotherapy is well tolerated and easily handled with encouraging results. These results are dependent on the quality of the initial resection.